Medicus Pharma on Bloomberg World
Rhea-AI Summary
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari was interviewed on Bloomberg World on February 10, 2026, outlining the company's AI-driven drug development strategy and near-term clinical catalysts.
Management disclosed nearly $14 million of personal capital committed at $4 per share and highlighted a planned Phase 2 Skinject data readout in H1 2026 as a potential value catalyst.
Positive
- Executives committed nearly $14 million personal capital at $4 per share
- Planned Phase 2 Skinject data readout in H1 2026 as a near-term catalyst
- Company emphasizes AI-driven approach to accelerate drug development
Negative
- Acknowledged short-term volatility in biotech markets that may affect share price
Market Reaction
Following this news, MDCX has gained 5.45%, reflecting a notable positive market reaction. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.00. This price movement has added approximately $1M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Within Pharmaceutical/Drug Manufacturers peers, names like MIRA, IXHL, SCYX, SCLX, and TLPH all showed negative moves, and momentum data highlighted RMTI down 4.5899998396635056%. With limited peers in momentum and a pre-news -7.77% move in MDCX, trading appeared more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | FDA trial clearance | Positive | -4.6% | FDA cleared Phase 2b Teverelix dose‑optimization study in high‑risk prostate cancer. |
| Jan 23 | Nasdaq anniversary event | Positive | +2.2% | Celebrated one-year Nasdaq listing and highlighted SkinJect and Teverelix programs. |
| Jan 22 | License amendment | Positive | +0.8% | Improved Teverelix economics via reduced royalty while keeping worldwide rights. |
| Jan 20 | Opening bell announcement | Positive | -1.4% | Planned Nasdaq Opening Bell and outlined multiple upcoming Phase 2 catalysts. |
| Jan 12 | Phase 1 data update | Positive | -5.8% | Reported favorable Phase 1 Teverelix data with hormone suppression and safety profile. |
Recent clinically and strategically positive announcements have often seen mixed to negative next-day price reactions, with more divergence than alignment.
Over the last month, Medicus Pharma has released multiple clinically focused and strategic updates, including an FDA "study may proceed" for a Phase 2b Teverelix trial on Feb 10, 2026 and several SkinJect Phase 2 and licensing milestones in January 2026. Despite generally constructive clinical and partnership news, price reactions have been inconsistent, with several negative moves following positive updates. This Bloomberg World interview fits into a period of active communication around AI-enabled development and Phase 2 catalysts.
Market Pulse Summary
The stock is up +5.5% following this news. A strong positive reaction aligns with management’s emphasis on AI-enabled development and insider capital committed at $4 per share. Historically, MDCX’s price response to positive clinical and strategic news has been mixed, with both aligned and divergent moves. Sustaining any upside would depend on how investors weigh this visibility campaign against prior patterns where favorable Phase 2 and licensing updates in Jan–Feb 2026 did not always translate into lasting gains.
Key Terms
phase 2 medical
clinical development programs medical
artificial intelligence technical
regulatory optionality regulatory
AI-generated analysis. Not financial advice.
Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller
PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Matt Miller from Bloomberg World for a live interview on February 10, 2026. https://youtu.be/2-naOb7uJRc?si=eumsbejKNkAdQ62G
In this live interview on Bloomberg World, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, discusses the company's strategy, the challenges facing biotech stocks, and how artificial intelligence is shaping its drug development efforts.
Central to the discussion is the role of AI in accelerating drug development. Dr. Bokhari outlines Medicus Pharma's AI-driven approach, positioning the company's leadership as both. investors and operators that have committed nearly
The conversation underscores both the short-term volatility in biotech markets and the company's long-term belief in the potential of AI to transform innovative therapy development.
Click here to watch the full interview.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.
SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumor cells. The Company completed a Phase 1 study (SKNJCT-001) in March of 2021, which met its primary objective of demonstrating safety and tolerability; the study also describes the efficacy of the investigational product doxorubicin-containing microneedle arrays (D-MNA), with six participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.
In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist, as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.
In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in 50 patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than
In January 2023, the U.S. Food and Drug Administration (FDA) reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev's proposed Phase 3 trial design for Teverelix. This milestone supports the Company's clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.
In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.
In November 2024, the FDA approved the Phase 2b study design in AURr covering 390 patients.
In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect in this rare disease population.
In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study-wide governance approval, confirming compliance with UK Good Clinical Practice and National Health Service capacity and capability standards.
In December 2025, the Company announced that it has successfully completed enrolment of 90 patients in the United States for Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.
In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences industry, to collaborate on the development of an AI-driven clinical data analytics platform. Subject to execution of definitive agreements, the platform is expected to support capital-efficient clinical development through data-driven dynamic clinical-site selection, patient stratification and enrollment forecasting. The initial phase of the collaboration is expected to support an upcoming Teverelix clinical study planned for 2026, with potential expansion into later-stage development programs in collaboration with a strategic partner.
In February 2026, Medicus announced that it has received "study may proceed" clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC).
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women's health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus's proprietary microneedle array (MNA) delivery platform, the Company's aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company's submission for approval in the FDA Commissioner's National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company's expectation to release topline results for SKNJCT-003 in the first quarter of 2026 and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
SOURCE: Medicus Pharma Ltd
View the original press release on ACCESS Newswire
FAQ
What did Medicus Pharma (MDCX) announce about insider funding in February 2026?
When will Medicus Pharma (MDCX) report Phase 2 Skinject results?
How is Medicus Pharma (MDCX) using artificial intelligence in drug development?
What did Medicus Pharma (MDCX) say about biotech market conditions in the interview?
Where and when did Medicus Pharma (MDCX) management discuss these updates?
